Raymond James Trust N.A. raised its position in Teladoc Health, Inc. (NYSE:TDOC – Get Rating) by 24.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 16,751 shares of the health services provider’s stock after acquiring an additional 3,329 shares during the quarter. Raymond James Trust N.A.’s holdings in Teladoc Health were worth $396,000 at the end of the most recent quarter.
A number of other institutional investors also recently bought and sold shares of TDOC. MetLife Investment Management LLC bought a new position in Teladoc Health in the first quarter valued at about $218,000. Panagora Asset Management Inc. raised its stake in shares of Teladoc Health by 18.8% in the first quarter. Panagora Asset Management Inc. now owns 16,710 shares of the health services provider’s stock worth $1,205,000 after buying an additional 2,640 shares during the period. Rhumbline Advisers raised its stake in shares of Teladoc Health by 2.3% in the first quarter. Rhumbline Advisers now owns 130,916 shares of the health services provider’s stock worth $9,443,000 after buying an additional 2,921 shares during the period. Great West Life Assurance Co. Can raised its stake in shares of Teladoc Health by 10.8% in the first quarter. Great West Life Assurance Co. Can now owns 107,908 shares of the health services provider’s stock worth $8,237,000 after buying an additional 10,559 shares during the period. Finally, Cibc World Market Inc. raised its stake in shares of Teladoc Health by 4.4% in the first quarter. Cibc World Market Inc. now owns 33,874 shares of the health services provider’s stock worth $2,443,000 after buying an additional 1,440 shares during the period. Institutional investors own 84.14% of the company’s stock.
Insider Transactions at Teladoc Health
In other news, SVP Daniel Trencher sold 1,000 shares of Teladoc Health stock in a transaction that occurred on Friday, March 17th. The stock was sold at an average price of $25.13, for a total value of $25,130.00. Following the completion of the transaction, the senior vice president now owns 25,520 shares in the company, valued at approximately $641,317.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, SVP Daniel Trencher sold 1,000 shares of the business’s stock in a transaction on Friday, March 17th. The stock was sold at an average price of $25.13, for a total transaction of $25,130.00. Following the completion of the transaction, the senior vice president now owns 25,520 shares in the company, valued at approximately $641,317.60. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Jason N. Gorevic sold 22,040 shares of the business’s stock in a transaction on Friday, March 3rd. The shares were sold at an average price of $25.91, for a total value of $571,056.40. Following the transaction, the chief executive officer now owns 603,434 shares of the company’s stock, valued at approximately $15,634,974.94. The disclosure for this sale can be found here. In the last 90 days, insiders sold 45,301 shares of company stock worth $1,180,135. 1.55% of the stock is currently owned by company insiders.
Teladoc Health Stock Performance
Teladoc Health (NYSE:TDOC – Get Rating) last announced its earnings results on Wednesday, February 22nd. The health services provider reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.04. The firm had revenue of $637.71 million during the quarter, compared to analysts’ expectations of $633.71 million. Teladoc Health had a negative return on equity of 4.35% and a negative net margin of 567.53%. Equities analysts forecast that Teladoc Health, Inc. will post -1.44 EPS for the current year.
Analyst Ratings Changes
Several research analysts have recently commented on the company. StockNews.com assumed coverage on Teladoc Health in a research note on Thursday, March 16th. They issued a “sell” rating on the stock. Stephens assumed coverage on Teladoc Health in a research note on Tuesday, April 11th. They issued an “equal weight” rating and a $25.00 price objective on the stock. SVB Securities raised Teladoc Health from a “market perform” rating to an “outperform” rating and set a $34.00 price objective on the stock in a research note on Thursday, February 23rd. Canaccord Genuity Group decreased their target price on Teladoc Health from $40.00 to $36.00 and set a “buy” rating on the stock in a research note on Monday, March 6th. Finally, Barclays decreased their target price on Teladoc Health from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 18th. One research analyst has rated the stock with a sell rating, nineteen have issued a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $34.35.
Teladoc Health Profile
Teladoc Health, Inc engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services.
Recommended Stories
- Get a free copy of the StockNews.com research report on Teladoc Health (TDOC)
- Medtronic: Reversal In-Play For This High-Yield Stock
- Is it ‘Game Over’ for Roblox After Reporting March Metrics Miss?
- Is it Time to Take Profits in Chip Stocks?
- Will Stratasys Continue to be a Runaway Bride?
- Garrett Motion Inc. Skids on Results: Is it Time to Buy the Dip?
Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health, Inc. (NYSE:TDOC – Get Rating).
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.
